Relay Therapeutics (RLAY)
NASDAQ:RLAY
RLAY Stock Chart & Stats
$9.44
>-$0.01(-0.22%)
At close: 4:00 PM EST
$9.44
>-$0.01(-0.22%)
Day’s Range― - ―
52-Week Range$1.78 - $11.49
Previous CloseN/A
Volume391.09K
Average Volume (3M)2.37M
Market Cap
$1.76B
Enterprise Value$1.66B
Total Cash (Recent Filing)$554.52M
Total Debt (Recent Filing)$32.46M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Apr 30, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding178,725,810
10 Day Avg. Volume2,970,330
30 Day Avg. Volume2,369,347
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue108.38
Enterprise Value/Gross Profit118.80
Enterprise Value/Ebitda-5.72
Forecast
1Y Price Target
$17.67Price Target Upside87.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.54
Revenue Forecast (FY)$6.49M
Bulls Say, Bears Say
Bulls Say
Cash RunwayA substantial cash balance is expected to fund operations through multiple key clinical milestones, providing a reliable runway for ongoing development programs.
Clinical EfficacyZovegalisib combined with Faslodex demonstrated stronger efficacy signals in early testing compared with an approved PI3K-targeting regimen, increasing confidence that the pivotal study could meet its endpoints.
Development StrategyAdvancing zovegalisib across multiple large indications with planned data disclosures and plans for late-stage testing of triplet combinations highlights a clear strategy to expand into earlier lines of breast cancer treatment.
Bears Say
Competitive LandscapeProgress by large pharmaceutical competitors and recent industry acquisitions in the PI3Kα inhibitor field increase competitive pressure on the company's programs, which could limit market opportunity.
Partnership RiskA major pharmaceutical partner running its own head-to-head study introduces collaboration and competitive risks that could affect enrollment, regulatory positioning, or the company's planned first-line program.
R&D InvestmentResearch and development spending below analyst expectations may raise questions about execution or indicate shifting development priorities that could delay program timelines.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $1.77 and its highest was $11.49 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $1.76B.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 35 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.085.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 178,725,810 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went up 12.009%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.67 (87.18% Upside)
$17.67 (87.18% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $724.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
204.51%
12-Months-Change
Fundamentals
Return on Equity
-43.17%
Trailing 12-Months
Asset Growth
-28.69%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$17.67
▲(87.18% Upside)
Technical Analysis
Ownership Overview
2.33% Insiders
9.29% Mutual Funds
53.23% Other Institutional Investors
23.05% Public Companies and
Individual Investors